

## Genesis Research Announces Half Year Results

Auckland, New Zealand, 30 August 2010 - **Genesis Research and Development Corporation Ltd (NZSX/ASX: GEN)** today reported a cash balance at 30 June 2010 of \$204,000 (31 December 2009: \$324,000) and a Net Loss for the period of \$0.5 million (30 June 2009: Net Loss \$ 1.2 million).

The net loss was substantially reduced due to cost reductions. Development of the new ssRNAi gene silencing technology was undertaken by Genesis under contract to its subsidiary company Solirna Biosciences Ltd. However, as Solirna was not able to raise sufficient funding to continue the project, the company's operations were suspended and all staff were made redundant at the end of May.

Genesis Chief Executive, Stephen Hall, said, "This has been a very challenging period for the company as it ceased active operations. However a number of parties are interested in investing in Solirna so we are hopeful that its ssRNAi research programme, which achieved progressively improving results, can be continued. Genesis is now pursuing opportunities for the development of new products in the dairy industry.

"Real Time Genomics Inc continues to make excellent progress with development of its advanced software for genomic analysis and recently announced a significant commercial licence to The Genome Center at Washington University in St. Louis.

"Since balance date Genesis terminated the lease of its premises by agreeing to pay \$150,000, which is equivalent to approximately five months rent. This settlement was funded by a loan of \$250,000 from UBNZ Funds Management Ltd which is convertible into 4,166,666 ordinary shares if conversion is approved by shareholders at a future meeting, or otherwise is repayable if conversion is not approved.

"UBNZ has advised that it is interested in making a further substantial investment in Genesis, which will be subject to shareholder approval at a meeting to be held shortly"

### **About Genesis**

Founded in 1994, Genesis is a New Zealand-based biotechnology company. It has built a broad therapeutic development platform targeting immune disorders and cancer. It has established Solirna Biosciences Ltd which is focusing on developing a novel single stranded gene silencing technology using the RNAi mechanism. Genesis also holds an equity interest in Real Time

Genomics Inc. and has royalty rights resulting from previous collaborations for various products that are being developed by other parties in the fields of agriculture, forage grass, forestry, etc. For further information see [www.genesis.co.nz](http://www.genesis.co.nz)

For further information see [www.genesis.co.nz](http://www.genesis.co.nz)

**Media contacts:**

Stephen Hall, Chief Executive - Genesis Research and Development Corporation Limited  
+64 21 715 725

Aki von Roy, Chairman- Genesis Research and Development Corporation Limited  
+64 21 556 659